Kornimate/medical-research-clean huggingface dataset:
does continuous vital sign monitoring increase investigations and interventions in complication-free patients?

Conditions: Cancer; Chronic Obstructive Pulmonary Disease; Surgery-Complications

Summary: this aim of this study is to investigate whether active alerts during cvsm result in an increased number of diagnostic tests and treatments in complication free patients, hypothesizing that more interventions are performed in the cvsm-group than standard of care (ews) group.


Eligibility criteria:
inclusion criteria: * • patients from ward - rct. exclusion criteria: -
ultrasound-guided pudendal nerve block for pain after hemorrhoidectomy

Conditions: Hemorrhoids; Postoperative Pain

Summary: the goal of this clinical trial is to investigate the effects of ultrasound-guided pudendal nerve block on postoperative pain, opioid consumption, and quality of recovery in patients receiving ferguson hemorrhoidectomy.

patients who have symptomatic hemorrhoids undergoing ferguson hemorrhoidectomy under spinal anesthesia will be randomized to receive bilateral ultrasound-guided pudendal nerve block with 0.5% ropivacaine or normal saline immediately after surgery. in addition, intravenous patient controlled analgesia, nsaids, and acetaminophen will be used in all participants for postoperative pain control. postoperative pain on numerical rating scale (nrs), opioid consumption, quality of recovery (qor-15), patient's satisfaction, and complications will be recorded at 6, 12, 24, 48 hours and 7 days after surgery.

Eligibility criteria:
inclusion criteria: * patients with symptomatic hemorrhoids (grade iii and grade iv internal hemorrhoids, mixed hemorrhoids, and external hemorrhoids) * age 20 to 65 years old * american society of anesthesiologists (asa) classification i\~iii * receiving ferguson hemorrhoidectomy under spinal anesthesia exclusion criteria: * allergy to local anesthetics or analgesics used in this study * drug abuse * coagulopathy * an active infection at the injection site * patient refusal * bmi ≥ 30 * pregnancy
post-approval study protocol of the st. jude medical trifecta valve

Conditions: Heart Valve Diseases

Summary: to further evaluate the long term clinical safety and effectiveness of the trifecta valve

to further evaluate the long term clinical safety and effectiveness of the trifecta valve in subjects who had a trifecta valve implanted during the ide study.

Eligibility criteria:
inclusion criteria: * subjects implanted with a trifecta valve at one of the us sites of the ide study. * subject met eligibility criteria of ide study * subject agrees to complete study follow-up visits * subject provides written informed consent exclusion criteria: * subject currently participating in another device or drug study * subject unable or unwilling to return for study follow-up visits

Keywords: trifecta valve
comparison of the incidence of dyskinesia in parkinson's disease who were treated with amantadine or dopamine agonist

Conditions: Parkinson's Disease

Summary: the purpose of this study is to compare the onset time and severity of dyskinesia in amantadine or dopamine agonist initial treated groups in parkinson's disease.

1. dopamine agonist can delay the risk of dyskinesia by initiating treatment rather than levodopa. amantadine is typical antidyskinetic drug. there is no data about comparison of risk of dyskinesia in amantadine and dopamine agonist by initiating treatment. 2. prospective , randomized, open label study compare the onset time and severity of dyskinesia between groups randomized assigned order of amantadine and dopamine agonist

Eligibility criteria:
inclusion criteria: * 30\<age\<60 * ipd * h \& y\<3 exclusion criteria: * previous dopaminergic medication history * dyskinesia * parkinson plus * clinically significant or unstable medical or surgical condition

Keywords: parkinson's disease
validation of a novel cortical biomarker signature for pain

Conditions: TMD

Summary: the study aims to undertake analytical validation of an brain biomarker in healthy participants experiencing a model of sustained temporomandibular pain. the biomarker could detect participants at greater risk of developing more severe pain.

chronic pain is a major health burden associated with immense economic and social costs. predictive biomarkers that can identify individuals at risk of developing severe and persistent pain, which is associated with worse disability and greater reliance on opioids, would promote aggressive, early intervention that could halt the transition to chronic pain. the investigative team has uncovered evidence of a unique cortical biomarker signature that predicts pain susceptibility (severity and duration). the biomarker signature combines resting state sensorimotor peak alpha frequency (paf) measured using electroencephalograph (eeg) and corticomotor excitability (cme) measured using transcranial magnetic stimulation (tms). this paf/cme biomarker signature could be capable of predicting the severity of pain experienced by an individual minutes to months in the future, as well as the duration of pain (time to recovery). in the current study, the investigators aim to undertake analytical validation of this biomarker in healthy participants using a standardized model of the transition to sustained myofascial temporomandibular pain (masseter intramuscular injection of nerve growth factor). the investigators will record paf/cme at multiple time points before and during the development of pain and use online diaries and in-laboratory assessments of pain, sleep, stress, and other psychosocial variables. specifically, the investigators will test if the biomarker signature predicts an individual's pain sensitivity (high- or low-pain sensitive).

Eligibility criteria:
inclusion criteria: * healthy exclusion criteria: * unable or refusal to provide written consent * presence of any acute pain disorder * history or presence of any chronic pain disorder * history or presence of any other medical or psychiatric compliant * use of opioids or illicit drugs in the past 3 months * pregnant or lactating women * excessive alcohol use * contraindicated for tms (metal implants, epilepsy)
bay 0 9867 cipro pediatric use study (quip)

Conditions: Infectious Diseases

Summary: objective and subjective musculoskeletal evaluations will be performed to determine differences in the ciprofloxacin versus non-quinolone treated pediatric patients so that we can tell what the natural occurrence of such musculoskeletal conditions is in the general pediatric population.

this study is classified as "interventional" due to study-specific medical examinations and interventions. regarding the study drug intake, routine administration is observed only, there is no intervention in study drug administration.

Eligibility criteria:
inclusion criteria: * patient is \>/= 2 months of age through 16 years of age * a parent/caregiver must sign an informed consent * patient must provide assent, as appropriate based on local institutional review board guidelines exclusion criteria: * patients presenting with the following conditions: * exacerbations of cystic fibrosis (cf) * meningitis * brain abscess * bacterial endocarditis, * bone and joint infections * having any of the following conditions but lacking a personal history may be admitted to the trial: * arthritis * juvenile rheumatoid arthritis (jra) * rheumatoid arthritis (ra) * systemic lupus erythematosis (sle) * history of rheumatic fever * psoriasis * inflammatory bowel disease * osteoarthritis (oa) * known underlying rheumatological disease, joint problems known to be associated with arthropathy. * patients with any pre-treatment baseline musculoskeletal exam abnormalities * known risk of experiencing seizures, a history of any convulsive disorders * requiring any concomitant therapeutic course of systemic antibacterial agent * participation in any industry-sponsored clinical drug development study within one month prior to this study * known significant liver impairment (alat/asat and/or baseline bilirubin \> 3 times upper limit of normal) * known significant renal insufficiency (calculated creatinine clearance of \< 30 ml/min/1.73 m²) * are pregnant or lactating, or are sexually active and using unreliable contraception.

Keywords: pediatrics safety musculoskeletal system neurologic manifestations joint diseases joint deformities, acquired
a protocol to streamline dental care in autistic children

Conditions: Autism Spectrum Disorder

Summary: the investigators aim at creating a dedicated pathway to allow accessibility to dental care for asd children within a hospital dentistry department, in order to diminish the need for general anesthesia. visual pedagogy, parent training, a strict schedule for appointments (every two months) spanning over three years and longer duration of dedicated examination are set up for a group of asd children, whose behavior is compared to that of children seen one or twice a year.

treated group: enrollment: caregivers receive instructions and a visual pedagogy aid with instructions for toothbrushing. they complete also enrollment and informed consent forms. at the first visit: caregivers receive a dental mirror to be used at home. children are free to explore the office and dental room. subsequent visits, every two months for three years: trials are made to establish contact with children, make them seat at the dentist's chair, execute dental visits and treatments as needed. control group: subjects (similar inclusion and exclusion criteria) that access the department for clinical reasons or control visits, but cannot comply with the strict two-months schedule.

Eligibility criteria:
inclusion criteria: * age: 4 to 13 years old at the beginning of the treatment, * diagnosis: formally diagnosed by a neuro-psychiatrist and recognized by authorities (for school support) as having autistic spectrum disorder (asd), possibly also in the frame of genetic syndromes, or pervasive developmental disorder-not otherwise specified (pdd-nos), a diagnosis present in dsm 4 and merged to asd in dsm 5. exclusion criteria: * age outside the selected range * additional diseases, preventing autonomous oral hygiene (e.g., motor diseases), * for the treated group: familiarity with dental treatments (possible one or few visits in the past, but not on a regular base)

Keywords: autism dentistry
pharmacokinetics of inhaled levosimendan

Conditions: Left Ventricular Dysfunction

Summary: determination of biological availability, time-to-peak and elimination half-life of inhaled levosimendan by administration of an inhaled- and intravenous dose of levosimendan.


Eligibility criteria:
inclusion criteria: * subject \>18 years of age * scheduled for elective coronary artery bypass grafting (cabg) * provided written informed consent * impaired left ventricular function (lvef \<40%) exclusion criteria: * known allergy for levosimendan or solutes * persistent angina, defined as canadian cardiovascular society score \> i * history of valvular intervention or uncorrected primary stenotic valve disease * uncorrected thyroid disease * infiltrative, hypertrophic or restrictive cardiomyopathy * pericardial disease * active myocarditis * chronic obstructive pulmonary disease requiring long-term treatment with β-agonists, theophylline, or corticosteroids (fev1 \< 80%; tiffeneau-index \<0.7) * history of serious arrhythmias, defined as a history of ventricular tachycardia or fibrillation other than that occurring within 24 hours after acute myocardial infarction (mi) * resting heart rate \> 115 bpm for at least 10 minutes on repeated measurements * supine systolic blood pressure \ 200 mm hg * patients with implanted pacemaker/defibrillator or cardiac resynchronisation therapy (crt-device) * primary renal or hepatic impairment (creatinine \> 2.5 mg/dl or aspartate aminotransferase/alanine aminotransferase \>2 times upper limit of normal and/or increased level of bilirubin (\> 2 times the upper limit of normal and increase of international normalised ratio (inr) above the upper limit of normal, respectively) * uncorrected hypokalemia or hyperkalemia (potassium \ 5.5 mmol/l) * uncorrected hypomagnesemia (magnesium \<0.65mmol/l) * treatment with another investigational agent within 30 days before study entry * intubated and mechanically ventilated at the time of study entry

Keywords: levosimendan inhalation pharmakokinetic
early upper limb rehabilitation with eeg-neurofeedback after stroke

Conditions: Stroke; Stroke Hemorrhagic; Stroke, Ischemic; Stroke Rehabilitation; Brain Infarction

Summary: the aim of this study is to evaluate the effect of early rehabilitation treatment by electroencephalographic neurofeedback on upper limb motor function after stroke. researchers will compare : interventional group: electroencephalographic neurofeedback + traditional reference rehabilitation programme control group: sham electroencephalographic neurofeedback + traditional reference rehabilitation programme


Eligibility criteria:
inclusion criteria: * unilateral ischaemic or haemorrhagic stroke * adult (18-80 years), both sexes * stroke \< 3 weeks * upper limb deficit defined by shoulder abduction finger extension score \<5 on day 3 of stroke; i.e., patients predicted to have incomplete recovery * no participation-limiting comprehension problems * with or without homonymous lateral hemianopia; with or without visuospatial hemineglect * free, informed and written consent signed by the patient or a member of the patient's family (in the case of a patient who is able to understand the information and give consent but has motor difficulties resulting in an invalid signature). * affiliated to french social security exclusion criteria: * ischemic or hemorrhagic brain stem and/or cerebellum involvement * multiple strokes * stroke \< 1 week; in order not to be deleterious by starting active rehabilitation too early after immediate stroke * aphasia with major comprehension impairment * contraindication to mri * pacemaker or implantable defibrillator, * neurosurgical clips, * cochlear implants, * intra-orbital or encephalic metallic foreign bodies, * stents placed less than 4 weeks ago and osteosynthesis devices placed less than 6 weeks ago, * claustrophobia.

Keywords: stroke rehabilitation neurofeedback upper limb
accuracy of guided implant placement using double versus triple scan protocol in completely edentulous patients

Conditions: Dental Implantation

Summary: 16 implant placement by surgical guide using double scan protocol versus triple scan protocol to evaluate angular and linear deviation of virtual implants and actual implant position in completely edentulous patients according to scanning protocol c1(double scan technique) and c2 (triple scan technique) .

in this study we discuss linear and angular deviation of actual implant position using planning protocol c1(double scan technique) or c2 (triple scan technique) in completely edentulous patient . both protocols c1(double scan technique) and c2 (triple scan technique) indicated in completely edentulous patient and require c.t scan for patient wearing scan appliance . in c1(double scan technique) , after ct scan for patient wearing scan appliance , two optical scan for the model with and without scan appliance. in c2 (triple scan technique) , after ct scan for patient wearing scan appliance , ct scan for scan appliance alone . teeth positions in both protocols were identified by radio-opaque scan appliance . 16 implant placement by surgical guide using double scan protocol versus triple scan protocol ( two groups - 8 implants in each group ) to evaluate angular and linear deviation of virtual implants and actual implant position in completely edentulous patients according to scanning protocol c1(double scan technique) and c2 (triple scan technique) .

Eligibility criteria:
inclusion criteria: 1. patients totally edentulous arches. 2. patients with bucco-lingual bone thickness \>6 mm allowing flapless implant placement 3. patients free from any systemic diseases that may affect bone quality e.g diabetes. exclusion criteria: 1. patients with thin ridges. 2. patients with systemic disease that may affect bone quality. 3. patients with poor oral hygiene and active periodontal diseases. 4. anatomical situations requiring regenerative procedure.

Keywords: surgical guide , double scan , triple scan protocol
weight reduction with the low-insulin-method - self monitoring of breath acetone

Conditions: Overweight and Obese Volunteers

Summary: the goal of this clinical trial is to learn if lifestyle intervention with information about ketosis state supports weight reduction in overweight adults. researchers will compare an app-based lifestyle intervention with self-monitoring of breath acetone vs. lifestyle intervention alone. participants will: get a lifestyle intervention via the lim-app for 12 months. report body weight.

background: overweight and obesity are an increasing problem. therefore, the low-insulin-method was developed to support overweight and obese people in weight loss. method: in a randomized controlled clinical trial, the effect of the lifestyle intervention program 'low-insulin-method', delivered by the low-insulin-app including low-carb diet, physical activity, self monitoring of weight, and self-monitoring of breath acetone (smba) is examined compared to a control group without information about ketosis level. weight change will be compared after 3 and 12 months. objective: the aim is to develop a training and counseling program for overweight or obese individuals with diabetes risk or type 2 diabetes, which can be used both for primary and for tertiary prevention of overweight-related diseases.

Eligibility criteria:
inclusion criteria: * body mass index \> 25kg/m2 exclusion criteria: -

Keywords: lifestyle intervention weight reduction ketosis
ptcy and atg for msd and mud transplants

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Hodgkin Lymphoma; Non-hodgkin Lymphoma

Summary: hematopoietic stem cell transplantation is a curative treatment for a number of benign and malignant hematologic diseases. one of the key parts of hematopoietic stem cell transplantation is the prophylaxis of graft-versus-host disease. since the end of the 1970s, with the introduction of cyclosporine, calcineurin inhibitors (cyclosporine and tacrolimus) have become part of almost all prophylactic regimens, even though they are a group of drugs with a poor toxicity profile that requires monitoring. constant serum level. since 2008, post-transplant cyclophosphamide has been introduced with great success, associated with a calcineurin inhibitor and mycophenolate, in the prophylaxis of graft-versus-host disease in haploidentical transplantation (50% matched). since then, in view of this enormous success, efforts have been made to incorporate post-transplant cyclophosphamide in matched related and unrelated transplants, or with a mismatch. this is a prospective, 2-arm, non-randomized study. arm 1, with related donors, and arm 2, with unrelated donors. patients will be allocated in these arms according to donor availability (patients with a matched-sibling donor will receive a matched-sibling transplant; patients with no related donors but with unrelated donors, an unrelated transplant). patients who are ready for transplantation with matched-sibling or unrelated donors will be recruited to participate in the study. the stem cell collection target will be 5e6 cd34/kg recipient weight for peripheral source. if a quantity greater than this is collected, the remainder will be cryopreserved according to the institutional protocol. graft-versus-host disease prophylaxis will be performed on d+3 and d+4 with cyclophosphamide and with atg on d-3 and d-2 for matched-sibling or unrelated donors transplants.


Eligibility criteria:
inclusion criteria: * patient with (1) acute leukemia in first or second remission; (2) myelodysplasia with less than 20% blasts; (3) hodgkin's or non-hodgkin's lymphoma, in partial remission after salvage therapy * who will receive a related or unrelated, hla-compatible transplant; * who is a transplant candidate with flumel, flutbi, cytbi, bucy or buflu conditioning; * peripheral blood source; * age between 18 and 60 years. exclusion criteria: - hepatic dysfunction (transaminases x2 the normal value)

Keywords: posttransplant cyclophosphamide atg calcineurin-free gvhd prophylaxis graft-versus-host disease
alternative antibiotic regimen in periodontitis treatment

Conditions: Amoxicillin; Metronidazole; Ofloxacin; Periodontitis; Root Planing

Summary: context and aims: several studies have demonstrated an association between obesity, periodontitis, and exercise. this study aimed to investigate the effects of regular exercise on obese women with periodontal disease, using serum, saliva, and gingival crevicular fluid (gcf) samples. settings and design: a before-after study design was adopted to evaluate the effects of 12 weeks of regular exercise on obese women grouped according to periodontal status, without a control group (no exercise). methods and material: the study sample comprised fifteen patients without periodontitis (np group) and 10 patients with chronic periodontitis (cp group), from whom periodontal parameters were measured and serum, saliva, and gcf samples were collected. body mass index (bmi), anthropometric measurements, somatotype-motoric tests, and maximal oxygen consumption (vo2max) were recorded at baseline and after exercise. statistical analysis used: medcalc was used for statistical analysis.


Eligibility criteria:
inclusion criteria: * the periodontal diagnosis of participants with generalized periodontitis stage iii-iv/grade c. systemically healthy participants with generalized periodontitis were enrolled if they were between 18 and 40 years of age, and had no allergies to penicillin, metronidazole or quinolones, a history of antibiotic therapy or periodontal therapy within the preceding six months exclusion criteria: * subjects were excluded if they had any known systemic diseases or conditions that can/could influence the periodontal status, allergies to quinolones, penicillin or metronidazole, a history of antibiotic therapy, or periodontal treatment within the preceding six months